Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Larimar Therapeutics, Inc. Common Stock

LRMR

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Last trade $3.04
Day change +$0.04 (+1.33%)
Day range $2.91 – $3.22
Volume 904,454
Market cap $312M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$311.65M
Price / earnings
—
Price / book
2.45×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.23×

Profitability

Earnings per share
-$1.66
Return on assets
-104.42%
Return on equity
-135.5%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.7×
Quick ratio
4.7×
Cash ratio
2.71×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$156.08M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LRMR, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$6.35M$6.09M$4.65M$4.57M$4.42M$4.64M$4.56M$4.35M
Research and development$28M$25.03M$59.37M$44.93M$23.37M$26.55M$26.74M$13.92M
Total operating expenses$34.35M$31.12M$64.02M$49.5M$27.79M$31.19M$31.29M$18.26M
Operating income-$34.35M-$31.12M-$64.02M-$49.5M-$27.79M-$31.19M-$31.29M-$18.26M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$32.78M-$29.61M-$62.5M-$47.71M-$26.18M-$29.28M-$28.82M-$15.5M
Income taxes$0$0$0$0$0$0$0$0
Net income-$32.78M-$29.61M-$62.5M-$47.71M-$26.18M-$29.28M-$28.82M-$15.5M
Net income attributable to common shareholders-$32.78M-$29.61M-$62.5M-$47.71M-$26.18M-$29.28M-$28.82M-$15.5M
EBITDA-$34.29M-$31.05M-$63.93M-$49.41M-$27.71M-$31.1M-$31.22M-$18.19M
Basic earnings per share-$0.30-$0.31-$0.73-$0.61-$0.41-$0.46-$0.45-$0.24
Diluted earnings per share-$0.30-$0.31-$0.73-$0.61-$0.41-$0.46-$0.45-$0.24

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Larimar stock has declined 22.7% over the past four weeks and is now in oversold territory with an RSI reading of 28.31, suggesting a potential trend reversal. Analysts have raised earnings estimates by 5% over the last 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, indicating potential near-term price appreciation.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics regarding its nomlabofusp drug candidate for Friedreich's Ataxia. The company's stock fell significantly after disclosing serious safety concerns—anaphylaxis in 7 participants in September 2025 and in 10 of 43 patients by June 2026—despite characterizing the data as 'positive' in press releases.

Benzinga

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The offering is expected to close on February 27, 2026, with proceeds to be used for development of nomlabofusp and general corporate purposes. J.P. Morgan and Guggenheim Securities are serving as joint bookrunning managers.

GlobeNewswire Inc.

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics priced an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to support development of nomlabofusp for Friedreich's ataxia and for general corporate purposes. The offering is expected to close on February 27, 2026, with J.P. Morgan and Guggenheim Securities as joint bookrunning managers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.